Skip to main content

HRMY

Stock
Health Care
Biotechnology

Performance overview

HRMY Price
Price Chart

Forward-looking statistics

Beta
0.60
Risk
51.11%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

Company info

SectorHealth Care
IndustryBiotechnology
Employees233
Market cap$1.7B

Fundamentals

Enterprise value$1.5B
Revenue$744.9M
Revenue per employee
Profit margin20.50%
Debt to equity24.63

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$2.62
Dividend per share
Revenue per share$13.06
Avg trading volume (30 day)$22M
Avg trading volume (10 day)$22M
Put-call ratio

Macro factor sensitivity

Growth+0.4
Credit+4.3
Liquidity-0.1
Inflation-3.0
Commodities-1.0
Interest Rates-2.0

Valuation

Dividend yield0.00%
PEG Ratio9.87
Price to sales2.48
P/E Ratio9.87
Enterprise Value to Revenue1.99
Price to book2.56

Upcoming events

Next earnings dayMay 6, 2025
Next dividend day
Ex. dividend day

News

Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again

Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research (July 17, 2025)
HRMY vs. ILMN: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research (July 15, 2025)
Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment

HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.

Zacks Investment Research (July 4, 2025)
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder

On Wednesday, Harmony Biosciences Holdings, Inc. HRMY received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH).

Benzinga (February 19, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free